Herceptin’s revenue trends
Roche’s (RHHBY) Herceptin reported revenues of 1.77 billion Swiss francs in the first quarter compared to 1.76 billion Swiss francs in the first quarter of 2017, which reflected ~2.0% YoY (year-over-year) growth at constant exchange rates. In the fourth quarter of 2017, Herceptin reported revenues of 1.78 billion Swiss francs, which reflects a flat revenue trend compared to the first quarter.
In the United States, Europe, and Japan, Herceptin generated first-quarter revenues of 728.0 million Swiss francs, 551.0 million Swiss francs, and 59.0 million Swiss francs, respectively. These revenues represented ~13.0% growth, a 3.0% decline, and a 10.0% decline YoY, respectively.
The sales growth in the US market pushed Herceptin’s growth in the first quarter. Herceptin is used in the treatment of individuals with HER2-positive breast cancer and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.
Kadcyla’s revenue trends
Roche’s Kadcyla generated revenues of 235.0 million Swiss francs in the first quarter, compared to 222.0 million Swiss francs in the first quarter of 2017, which reflected ~6.0% YoY growth and a 3.0% sequential decline.
In the United States, Europe, and Japan, Kadcyla generated first-quarter revenues of 86.0 million Swiss francs, 92.0 million Swiss francs, and 16.0 million Swiss francs, respectively, which reflected YoY growth of ~2.0%, 1.0%, and 1.0%.
In the international markets (outside the United States, Europe, and Japan), Kadcyla reported first-quarter revenues of 41.0 million Swiss francs, which reflected ~33.0% YoY growth.
The revenue growth in the international market primarily pushed Kadcyla’s revenue growth in the first quarter. Kadcyla is used for the treatment of HER2-positive metastatic breast cancer for patients who underwent prior therapy with Herceptin and taxane. In the HER2-positive metastatic breast cancer drugs market, Roche’s Herceptin competes with Novartis (NVS) Tykerb and Puma Biotechnology’s (PBYI) Nerlynx.
In the next article, we’ll discuss Roche’s HER2 drug Perjeta.